Glibenclamide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Glibenclamide

Examples of brand names: Euglucon [DE]

ATC code: A10BB01

Main use (for orientation): Type 2 diabetes

Documented research summary

Human ex-vivo placental perfusion and cell models show CBD-influenced glyburide transport, not a clinical pregnancy trial. Rat vascular experiment: THC-induced vasorelaxation was not inhibited by glibenclamide. No evidence establishing or excluding general combined hypoglycaemia risk.

Uncertainties and limitations

The abstract incorrectly expands the F/M ratio as female/male; no exact ratio adopted without the full text.

Older US label version documented; no current German market assessment.

PMC1576168 full-text retrieval returned HTTP 500; do not describe abstract access as full-text access.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0401

Type of result: Preclinical transport finding

Observation: CBD increased fetal glyburide penetration in the isolated perfused placenta model.

Mechanism: BCRP-related transport

Study type: Human placenta ex vivo and cell models

Context studied: Glyburide 200 ng/ml; 8 CBD-treated and 8 control cotyledons according to the abstract; additional BeWo/Jar cell experiments.

Clinical interpretation: Interpret within the stated study context; no independent dosage or treatment recommendation.

Limitations and uncertainties: Not a clinical investigation in pregnant women. Numerical F/M ratio not adopted because the abstract abbreviation was expanded incorrectly. Do not infer established fetal injury from this experiment.

Original sources for this finding: Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. [BMED23933222]

THC – laboratory and animal studies

Finding ID: B0402

Type of result: Preclinical null finding

Observation: Glibenclamide did not block THC-induced mesenteric vasorelaxation in the model investigated.

Mechanism: KATP channel test

Study type: Isolated rat arteries

Context studied: Vascular pharmacology, not diabetes treatment.

Clinical interpretation: Interpret within the stated study context; no independent dosage or treatment recommendation.

Limitations and uncertainties: Full text inaccessible; limited null finding. No conclusion about glucose control or human safety.

Original sources for this finding: The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. [CA_P_15821751]

References and access status

[RLABEL_D0242] Glibenclamid – DailyMed Produktkennzeichnung

Original source / bibliographic reference

Authors: Regulatory product information; respective marketing authorisation holder

Year: 2015

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED23933222] Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study.

Original source / bibliographic reference

Authors: Feinshtein V, Erez O, Ben-Zvi Z, Eshkoli T, Sheizaf B, Sheiner E, Holcberg G.

Year: 2013

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.ajog.2013.08.005

PMID: 23933222

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[CA_P_15821751] The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide.

Original source / bibliographic reference

Authors: O'Sullivan SE, Kendall DA, Randall MD.

Year: 2005

Source type: Primary / secondary publication; design and use described in the individual review

DOI: 10.1038/sj.bjp.0706218

PMID: 15821751

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility